← FDA DRUG APPROVALS

FDA ANDA · ANDA090711

KIRKLAND SIGNATURE NICOTINE

nicotine

Sponsor: PPI-DAC

APPLICATION
ANDA090711
TYPE
ANDA
ORIGINAL APPROVAL
2009-07-10
LATEST ACTION
2016-07-21
ROUTE
ORAL
DOSAGE FORM
TROCHE/LOZENGE
MARKETING STATUS
Over-the-counter

Products

NICOTINE POLACRILEXOver-the-counter
NICOTINE POLACRILEX EQ 2MG BASE · TROCHE/LOZENGE · ORAL
NICOTINE POLACRILEXOver-the-counter
NICOTINE POLACRILEX EQ 4MG BASE · TROCHE/LOZENGE · ORAL

Approval history

2016-07-21Labeling · Supplement 20AP
2016-06-23Manufacturing (CMC) · Supplement 16 · unknownAP
2016-06-23Labeling · Supplement 14 · standardAP
2016-06-23Labeling · Supplement 10 · standardAP
2009-07-10OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →